Delaney William E IV, the Chief Scientific Officer of Assembly Biosciences, Inc., has acquired 13,705 shares of the company's common stock. This acquisition comes as part of a performance-based restricted stock unit award, which was contingent on achieving specific performance milestones.

The filing, submitted on November 3, 2026, highlights the importance of executive incentives in the pharmaceutical preparations sector. With the acquisition, Delaney now holds a total of 74,035 shares in Assembly Biosciences.

Background

Assembly Biosciences, Inc. operates in the pharmaceutical preparations industry, focusing on innovative treatments. The company, incorporated in Delaware, is based in South San Francisco, California. Its stock is traded under the symbol ASMB. Recent filings indicate that the company is actively engaging its executives through performance-based compensation strategies.

What the Filing Says

"Represents shares of common stock issuable under a performance-based restricted stock unit award dated June 16, 2025. On October 30, 2026, a performance-based vesting condition was achieved."

The filing details that the shares acquired by Delaney are part of a performance-based vesting condition achieved on October 30, 2026. These shares will vest in two equal installments, with the next installment expected on October 30, 2027.

Impact

This acquisition may affect Assembly Biosciences' internal dynamics by aligning executive interests with company performance, potentially driving further innovation and growth. The pharmaceutical preparations industry will be watching closely, as such moves can set precedents for executive compensation practices across the sector.

What's Next

The filing does not say what happens next.